Russia Develops mRNA Flu Vaccine That Can Be Reprogrammed for a New Strain in Two Weeks
Siberian scientists have created a multivalent vaccine based on matrix RNA that solves epidemiologists' biggest headache—antigenic drift of the virus. If a strain mutates in the middle of the season, the drug can be quickly modified without stopping the production cycle.
Every autumn, the World Health Organization guesses which flu strain will hit six months later. Sometimes it gets it right. Sometimes it doesn't—and then millions of people receive a vaccine that works at half strength. On April 24, 2026, the Novosibirsk center "Vector" patented a technology that makes this guessing unnecessary. Their mRNA flu vaccine can be reprogrammed for a new strain in two weeks—right in the middle of the epidemic season, without retooling the factory or launching a new production cycle.
The War on Mutations We've Finally Started Winning
Scientists at Vector have created a multivalent platform that targets not just one strain but covers several variants of influenza A and B at once. The foundation is a DNA template on which messenger RNA is synthesized, encoding hemagglutinin—the surface protein the virus uses to attach to cells. Has the protein changed due to mutation? You change the template section, and the conveyor belt produces an updated version.
Vladimir Koval, Director of the Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, explained the mechanics without mincing words: today the whole world relies on WHO forecasts, which analyze circulating strains and issue recommendations. But if the strain changes mid-season—and the flu knows how to do that—pharma companies can't do anything. Their vaccine is already bottled. "mRNA technology fundamentally solves this problem: a new vaccine for the changed strain can be developed in two weeks," Koval stated.
In preclinical trials on mice, the vaccine showed a strong immune response: both specific antibodies and T-cell immunity were formed. Antibody levels to hemagglutinin significantly exceeded control values. To increase mRNA stability, the developers incorporated modified uridine into its structure—the same trick used by Pfizer/BioNTech and Moderna in their COVID vaccines.
Larisa Karpenko, leading researcher at Vector's Department of Bioengineering, revealed another detail at the OpenBio-2025 forum: the team is testing jet injection—where the vaccine liquid under pressure penetrates the skin and reaches the muscles without a needle. Moreover, with this method of administration, mRNA can work even without a lipid envelope—in "naked form." This radically simplifies logistics and reduces cold chain requirements.
What's Already in Vector's Portfolio
The flu platform is not the center's only mRNA development. At the same OpenBio forum, Karpenko listed a lineup that takes your breath away: mRNA vaccines against monkeypox, HIV-1, tick-borne encephalitis, as well as therapeutic vaccines encoding broadly neutralizing antibodies to HIV.
For flu, the portfolio is already multivalent: a trivalent vaccine against H1N1, H3N2, and influenza B has passed immunogenicity and protective efficacy evaluation in animals. A vaccine against avian influenza H5N8 has been separately tested—and it protects against lethal infection not only with H5N8 but also with H5N1. For a country whose southern regions are a crossroads of wild bird migration routes, this is not a lab curiosity but a strategic asset.
The Vector Center is no newcomer to this game. It has one of the world's most comprehensive collections of viruses, including samples of Ebola, Marburg, SARS, and smallpox. It was on its basis that the government created the national laboratory for working with highly pathogenic influenza viruses. When it comes to rapid decoding of a new pathogen and synthesis of a vaccine candidate, Vector is the place they call first.
From the COVID Lesson to the Flu Platform
The mRNA technology didn't come out of nowhere. The COVID-19 pandemic turned it from a lab curiosity into the fastest-growing vaccine platform on the planet. According to a lecture by Professor Vladimir Gushchin of the Russian Academy of Sciences at Pirogov University, over five billion doses of mRNA vaccines have been administered worldwide in five years, and the safety profile is considered acceptable—no catastrophic side effects in terms of frequency or severity have been identified. Studies of long-term effects continue, but the window of opportunity is wide open.
Gushchin emphasized in the same lecture: the mRNA platform is a universal tool. It allows the creation of candidate drugs in two to three months, combination of antigens from different pathogens, and generation of antibodies to conserved regions of viral proteins—for example, to the "stalk" of influenza hemagglutinin, which hardly mutates. And, critically for flu, it enables rapid adaptation of the drug composition to new antigens.
In Russia, several mRNA competence centers are working in parallel. The Gamaleya Center is building a dedicated factory for mRNA vaccines and has already released the first test batches of a personalized anticancer vaccine "Neoonkovac." In November 2025, the Ministry of Health issued the world's first approval for its clinical use in patients with inoperable melanoma. The mRNA ecosystem in Russia is being assembled not around a single drug but as a full-fledged technological platform with a growing product portfolio.
The Pharma Market Gets a New Type of Product
A traditional flu vaccine is a predictable but inflexible product. Manufacturers commit to strains 6–8 months before the season, grow the virus on chicken embryos, inactivate, purify, and bottle. If the WHO gets the strain wrong, efficacy drops to 10–30%, as happened in the 2014–2015 season with H3N2. It's physically impossible to fix the situation mid-season.
The mRNA platform flips this model. Koval reported that the team is already presenting the development to pharma companies. For Russian manufacturers—Microgen, Forte, Biocad—this is a chance to enter the mRNA vaccine race not from scratch but with a ready-made platform that has passed preclinical validation. For the Ministry of Health, it's a tool for rapid response to pandemic threats without dependence on foreign suppliers.
The global context is also clear. Moderna and Pfizer are already developing mRNA flu vaccines, but their products are tailored to Western regulatory procedures and pricing models. The Russian development, with a patent and its own production stack, means sovereignty in a sector where the speed of response to mutation matters more than production capacity volume.
An additional win is storage. The Vector team has developed cryoprotectants that allow the vaccine to be stored in lyophilized form at +20°C for a month. For comparison, the first Pfizer mRNA vaccines required –70°C. If the lyophilized version confirms stability in longer trials, the vaccine could be delivered to regions without ultra-low-temperature freezers.
What Will Happen in the Next Three Years
The first stage is clinical trials. The patent has been obtained, preclinical studies in mice are complete. The next step is Phase I/II in humans. Given that Vector is under Rospotrebnadzor and has experience with accelerated development of the EpiVacCorona vaccine, the bureaucratic path is familiar. The priority scenario is trials in adult volunteers during 2026–2027.
The second stage is production scaling. Here, the Gamaleya Center's factory will play a key role; it has already produced test batches of mRNA vaccines and is fine-tuning GMP-compliant production. Vector and Gamaleya are not competing—they are building a common technological ecosystem where one team develops the platform and the other optimizes serial production.
The third vector is regulatory. The Ministry of Health has already set a precedent for accelerated approval of mRNA drugs by authorizing Neoonkovac for clinical use under a personalized protocol. For the flu vaccine, which is not personalized but population-based, the procedure will be standard, but the regulator's experience with mRNA products will shorten review time.
The fourth and most important forecast is international. Vector coordinates interaction with the WHO on HIV vaccine development. Similar cooperation on flu is a logical next step. If the Russian mRNA platform proves efficacy and safety in clinical trials, it could become an export product: countries without their own mRNA production could purchase not ready-made syringes but a platform adaptable to their regional strains.
Two weeks to reprogram a vaccine for a new strain is not evolution. It's a paradigm shift in which epidemiologists played catch-up with the virus and lost every time a mutation outpaced bureaucracy. With Vector's patents, the math changes: now the virus will have to run away from the vaccine, not the other way around.
— Editorial Team
